Kalapurakal John A, Dome Jeffrey S, Perlman Elizabeth J, Malogolowkin Marcio, Haase Gerald M, Grundy Paul, Coppes Max J
Department of Radiation Oncology, Children's Memorial Hospital, Northwestern University, IL, Chicago, USA.
Lancet Oncol. 2004 Jan;5(1):37-46. doi: 10.1016/s1470-2045(03)01322-6.
Most patients with Wilms' tumour in Europe and North America can be cured with treatment and subsequently lead a normal adulthood. However, for some, therapy as applied today results in long-term side-effects and creates a substantial burden on quality of life. Therefore, investigators involved in the management of patients with Wilms' tumour are increasingly focusing their efforts on curtailing the long-term sequelae of therapy. This aim has been achieved by lowering the total amount of chemotherapy, radiotherapy, or both administered to patients who have characteristics associated with favourable outcome. Although excellent survival has been maintained, many patients receive less therapy today than patients with similar characteristics did a decade or two ago. Better understanding of the biological processes that lead to this childhood cancer will allow further improvements in its management.
在欧洲和北美,大多数患有肾母细胞瘤的患者通过治疗可以治愈,并随后正常步入成年期。然而,对于一些患者来说,如今所采用的治疗方法会导致长期副作用,并给生活质量带来沉重负担。因此,参与肾母细胞瘤患者管理的研究人员越来越致力于减少治疗的长期后遗症。通过减少给予具有良好预后特征患者的化疗、放疗总量或两者的总量,这一目标已经实现。尽管保持了出色的生存率,但如今许多患者接受的治疗比一二十年前具有相似特征的患者要少。对导致这种儿童癌症的生物学过程有更深入的了解将有助于进一步改善其治疗。